Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide (Mounjaro): A Dual-Action Breakthrough for Type 2 Diabetes and Weight Loss Abstract Tirzepatide, marketed as Mounjaro, is a groundbreaking dual GIP and GLP-1 receptor agonist approved for the treatment of type 2 diabetes
B12 injections combat fatigue and support metabolism
The methodological robustness of the study, and consistency with recent literature support that use of GLP-1 RA does not appear to be associated with an increased risk of suicide or suicide attempts
People with a family history of medullary thyroid carcinoma (a type of thyroid cancer) or those with Multiple Endocrine Neoplasia syndrome type 2 should also avoid Semaglutide due to the potential risk of thyroid tumors
Liraglutide proved the least effective of the three drugs
We still have a lot to learn The goal has always been fat loss, not weight loss (or should be)
